Skip to main content
Top
Published in: Drug Safety 5/2008

01-05-2008 | Review Article

Drug-Induced Urinary Retention

Incidence, Management and Prevention

Authors: Dr Katia M. C. Verhamme, Miriam C. J. M. Sturkenboom, Bruno H. Ch Stricker, Ruud Bosch

Published in: Drug Safety | Issue 5/2008

Login to get access

Abstract

Urinary retention is a condition in which impaired emptying of the bladder results in postvoidal residual urine. It is generally classified into ‘acute’ or ‘chronic’ urinary retention. Because of the complex mechanism of micturition, many drugs can interact with the micturition pathway, all via different modes of action. Although the incidence of urinary retention, in particular acute urinary retention, has been well studied in observational studies and randomized controlled trials, data on the incidence of drug-induced urinary retention are scarce. Data from observational studies suggest that up to 10% of episodes might be attributable to the use of concomitant medication. Urinary retention has been described with the use of drugs with anticholinergic activity (e.g. antipsychotic drugs, antidepressant agents and anticholinergic respiratory agents), opioids and anaesthetics, α-adrenoceptor agonists, benzodiazepines, NSAIDs, detrusor relaxants and calcium channel antagonists. Elderly patients are at higher risk for developing drug-induced urinary retention, because of existing co-morbidities such as benign prostatic hyperplasia and the use of other concomitant medication that could reinforce the impairing effect on micturition. Drug-induced urinary retention is generally treated by urinary catheterization, especially if acute, in combination with discontinuation or a reduction in dose of the causal drug. Studies have been carried out examining the effects of preventive measures for anaesthesia-related urinary retention, both during and after surgery, particularly into the effect of using opioids in combination with non-opioid analgesic drugs on the incidence of postoperative urinary retention. Although combination therapy reduces the opioid-related adverse events, the effect on urinary retention yields contradictory results. This article reviews the literature on drug-induced urinary retention and focuses on its incidence, the different classes of drugs that have been associated with it, and options for its management and prevention.
Literature
1.
go back to reference Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 2002 Jul; 187(1): 116–26PubMedCrossRef Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 2002 Jul; 187(1): 116–26PubMedCrossRef
3.
go back to reference Roehrborn CG. Acute urinary retention: risks and management. Rev Urol 2005; 7 Suppl. 4: S31–41PubMed Roehrborn CG. Acute urinary retention: risks and management. Rev Urol 2005; 7 Suppl. 4: S31–41PubMed
4.
go back to reference Meigs JB, Barry MJ, Giovannucci E, et al. Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol 1999 Aug; 162(2): 376–82PubMedCrossRef Meigs JB, Barry MJ, Giovannucci E, et al. Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol 1999 Aug; 162(2): 376–82PubMedCrossRef
5.
go back to reference Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997 Aug; 158(2): 481–7PubMedCrossRef Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997 Aug; 158(2): 481–7PubMedCrossRef
6.
go back to reference Cathcart P, van der Meulen J, Armitage J, et al. Incidence of primary and recurrent acute urinary retention between 1998 and 2003 in England. J Urol 2006 Jul; 176(1): 200–4; discussion 4PubMedCrossRef Cathcart P, van der Meulen J, Armitage J, et al. Incidence of primary and recurrent acute urinary retention between 1998 and 2003 in England. J Urol 2006 Jul; 176(1): 200–4; discussion 4PubMedCrossRef
7.
go back to reference Verhamme KM, Dieleman JP, van Wijk MA, et al. Low incidence of acute urinary retention in the general male population: the triumph project. Eur Urol 2005 Apr; 47(4): 494–8PubMedCrossRef Verhamme KM, Dieleman JP, van Wijk MA, et al. Low incidence of acute urinary retention in the general male population: the triumph project. Eur Urol 2005 Apr; 47(4): 494–8PubMedCrossRef
8.
go back to reference Temml C, Brossner C, Schatzl G, et al. The natural history of lower urinary tract symptoms over five years. Eur Urol 2003 Apr; 43(4): 374–80PubMedCrossRef Temml C, Brossner C, Schatzl G, et al. The natural history of lower urinary tract symptoms over five years. Eur Urol 2003 Apr; 43(4): 374–80PubMedCrossRef
9.
go back to reference Roehrborn CG. The epidemiology of acute urinary retention in benign prostatic hyperplasia. Rev Urol 2001 Fall; 3(4): 187–92PubMed Roehrborn CG. The epidemiology of acute urinary retention in benign prostatic hyperplasia. Rev Urol 2001 Fall; 3(4): 187–92PubMed
10.
go back to reference Klarskov P, Andersen JT, Asmussen CF, et al. Acute urinary retention in women: a prospective study of 18 consecutive cases. Scand J Urol Nephrol 1987; 21(1): 29–31PubMedCrossRef Klarskov P, Andersen JT, Asmussen CF, et al. Acute urinary retention in women: a prospective study of 18 consecutive cases. Scand J Urol Nephrol 1987; 21(1): 29–31PubMedCrossRef
11.
go back to reference Glavind K, Bjork J. Incidence and treatment of urinary retention postpartum. Int Urogynecol J Pelvic Floor Dysfunct 2003 Jun; 14(2): 119–21PubMedCrossRef Glavind K, Bjork J. Incidence and treatment of urinary retention postpartum. Int Urogynecol J Pelvic Floor Dysfunct 2003 Jun; 14(2): 119–21PubMedCrossRef
12.
go back to reference Teo R, Punter J, Abrams K, et al. Clinically overt postpartum urinary retention after vaginal delivery: a retrospective case-control study. Int Urogynecol J Pelvic Floor Dysfunct 2006 Aug 23; 18(5): 521–4PubMed Teo R, Punter J, Abrams K, et al. Clinically overt postpartum urinary retention after vaginal delivery: a retrospective case-control study. Int Urogynecol J Pelvic Floor Dysfunct 2006 Aug 23; 18(5): 521–4PubMed
13.
go back to reference Turner-Warwick R. Impaired voiding efficiency and retention. Clin Obstet Gynaecol 1978 Apr; 5(1): 193–207PubMed Turner-Warwick R. Impaired voiding efficiency and retention. Clin Obstet Gynaecol 1978 Apr; 5(1): 193–207PubMed
14.
go back to reference Thomas K, Chow K, Kirby RS. Acute urinary retention: a review of the aetiology and management. Prostate Cancer Prostatic Dis 2004; 7(1): 32–7PubMedCrossRef Thomas K, Chow K, Kirby RS. Acute urinary retention: a review of the aetiology and management. Prostate Cancer Prostatic Dis 2004; 7(1): 32–7PubMedCrossRef
15.
go back to reference Murray K, Massey A, Feneley RC. Acute urinary retention: a urodynamic assessment. Brit J Urol 1984 Oct; 56(5): 468–73PubMed Murray K, Massey A, Feneley RC. Acute urinary retention: a urodynamic assessment. Brit J Urol 1984 Oct; 56(5): 468–73PubMed
16.
go back to reference Gatti JM, Perez-Brayfield M, Kirsch AJ, et al. Acute urinary retention in children. J Urol 2001 Mar; 165(3): 918–21PubMedCrossRef Gatti JM, Perez-Brayfield M, Kirsch AJ, et al. Acute urinary retention in children. J Urol 2001 Mar; 165(3): 918–21PubMedCrossRef
17.
go back to reference Kurasawa G, Kotani K, Kurasawa M, et al. Causes of chronic retention of urine in the primary care setting. Intern Med (Tokyo, Japan) 2005 Jul; 44(7): 761–2CrossRef Kurasawa G, Kotani K, Kurasawa M, et al. Causes of chronic retention of urine in the primary care setting. Intern Med (Tokyo, Japan) 2005 Jul; 44(7): 761–2CrossRef
18.
19.
go back to reference Kumar V, Templeman L, Chapple CR, et al. Recent developments in the management of detrusor overactivity. Curr Opin Urol 2003 Jul; 13(4): 285–91PubMedCrossRef Kumar V, Templeman L, Chapple CR, et al. Recent developments in the management of detrusor overactivity. Curr Opin Urol 2003 Jul; 13(4): 285–91PubMedCrossRef
20.
go back to reference Andersson KE, Chapple C, Wein A. The basis for drug treatment of the overactive bladder. World J Urol 2001 Nov; 19(5): 294–8PubMedCrossRef Andersson KE, Chapple C, Wein A. The basis for drug treatment of the overactive bladder. World J Urol 2001 Nov; 19(5): 294–8PubMedCrossRef
21.
go back to reference de Groat WC. Integrative control of the lower urinary tract: preclinical perspective. Brit J Pharmacol 2006 Feb; 147 Suppl. 2: S25–40CrossRef de Groat WC. Integrative control of the lower urinary tract: preclinical perspective. Brit J Pharmacol 2006 Feb; 147 Suppl. 2: S25–40CrossRef
22.
go back to reference Andersson KE, Hedlund P. Pharmacologic perspective on the physiology of the lower urinary tract. Urology 2002 Nov; 60 (5 Suppl. 1): 13–20; discussion 1PubMedCrossRef Andersson KE, Hedlund P. Pharmacologic perspective on the physiology of the lower urinary tract. Urology 2002 Nov; 60 (5 Suppl. 1): 13–20; discussion 1PubMedCrossRef
23.
go back to reference Woodring JH, Martin CA, Keefer B. Esophageal atony and dilatation as a side effect of thiothixene and benztropine. Hosp Community Psychiatry 1993 Jul; 44(7): 686–8PubMed Woodring JH, Martin CA, Keefer B. Esophageal atony and dilatation as a side effect of thiothixene and benztropine. Hosp Community Psychiatry 1993 Jul; 44(7): 686–8PubMed
24.
go back to reference Tueth MJ. Emergencies caused by side effects of psychiatric medications. Am J Emerg Med 1994 Mar; 12(2): 212–6PubMedCrossRef Tueth MJ. Emergencies caused by side effects of psychiatric medications. Am J Emerg Med 1994 Mar; 12(2): 212–6PubMedCrossRef
25.
go back to reference Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005 Jun 21; 172(13): 1703–11PubMedCrossRef Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005 Jun 21; 172(13): 1703–11PubMedCrossRef
26.
go back to reference Xomalis D, Bozikas VP, Garyfallos G, et al. Urinary hesitancy and retention caused by ziprasidone. Int Clin Psychopharmacol 2006 Jan; 21(1): 71–2PubMedCrossRef Xomalis D, Bozikas VP, Garyfallos G, et al. Urinary hesitancy and retention caused by ziprasidone. Int Clin Psychopharmacol 2006 Jan; 21(1): 71–2PubMedCrossRef
27.
go back to reference Bozikas V, Petrikis P, Karavatos A. Urinary retention caused after fluoxetine-risperidone combination. J Psychopharmacol 2001 Jun; 15(2): 142–3PubMedCrossRef Bozikas V, Petrikis P, Karavatos A. Urinary retention caused after fluoxetine-risperidone combination. J Psychopharmacol 2001 Jun; 15(2): 142–3PubMedCrossRef
28.
go back to reference Benazzi F. Urinary retention with fluoxetine-haloperidol combination in a young patient. Can J Psychiatry 1996 Nov; 41(9): 606–7PubMed Benazzi F. Urinary retention with fluoxetine-haloperidol combination in a young patient. Can J Psychiatry 1996 Nov; 41(9): 606–7PubMed
29.
go back to reference Benazzi F. Urinary retention with venlafaxine-haloperidol combination [letter]. Pharmacopsychiatry 1997 Jan; 30(1): 27PubMedCrossRef Benazzi F. Urinary retention with venlafaxine-haloperidol combination [letter]. Pharmacopsychiatry 1997 Jan; 30(1): 27PubMedCrossRef
30.
go back to reference Benazzi F. Urinary retention with sertraline, haloperidol, and clonazepam combination. Can J Psychiatry 1998 Dec; 43(10): 1051–2PubMed Benazzi F. Urinary retention with sertraline, haloperidol, and clonazepam combination. Can J Psychiatry 1998 Dec; 43(10): 1051–2PubMed
31.
go back to reference Ulmar G, Schunck H, Kober C. Urinary retention in the course of neuroleptic therapy with haloperidol. Pharmacopsychiatry 1988 Jul; 21(4): 208–9PubMedCrossRef Ulmar G, Schunck H, Kober C. Urinary retention in the course of neuroleptic therapy with haloperidol. Pharmacopsychiatry 1988 Jul; 21(4): 208–9PubMedCrossRef
32.
go back to reference Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine. Am J Psychiatry 1994 Apr; 151(4): 619–20PubMed Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine. Am J Psychiatry 1994 Apr; 151(4): 619–20PubMed
33.
go back to reference Lin CC, Bai YM, Chen JY, et al. A retrospective study of clozapine and urinary incontinence in Chinese in-patients. Acta Psychiatr Scand 1999 Aug; 100(2): 158–61PubMedCrossRef Lin CC, Bai YM, Chen JY, et al. A retrospective study of clozapine and urinary incontinence in Chinese in-patients. Acta Psychiatr Scand 1999 Aug; 100(2): 158–61PubMedCrossRef
34.
go back to reference Fuller MA, Borovicka MC, Jaskiw GE, et al. Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. J Clin Psychiatry 1996 Nov; 57(11): 514–8PubMedCrossRef Fuller MA, Borovicka MC, Jaskiw GE, et al. Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. J Clin Psychiatry 1996 Nov; 57(11): 514–8PubMedCrossRef
35.
go back to reference Pradhan SC. Clozapine-induced urinary incontinence: facts or artefacts? Acta Psychiatr Scand 2000 May; 101(5): 410PubMedCrossRef Pradhan SC. Clozapine-induced urinary incontinence: facts or artefacts? Acta Psychiatr Scand 2000 May; 101(5): 410PubMedCrossRef
36.
go back to reference Warner JP, Harvey CA, Barnes TR. Clozapine and urinary incontinence. Int Clin Psychopharmacol 1994 Sep; 9(3): 207–9PubMedCrossRef Warner JP, Harvey CA, Barnes TR. Clozapine and urinary incontinence. Int Clin Psychopharmacol 1994 Sep; 9(3): 207–9PubMedCrossRef
37.
go back to reference Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf 1994 Jan; 10(1): 18–46PubMedCrossRef Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf 1994 Jan; 10(1): 18–46PubMedCrossRef
38.
go back to reference Benazzi F. Urinary retention with reboxetine-fluoxetine combination in a young man. Can J Psychiatry 2000 Dec; 45(10): 936PubMed Benazzi F. Urinary retention with reboxetine-fluoxetine combination in a young man. Can J Psychiatry 2000 Dec; 45(10): 936PubMed
39.
go back to reference Lock JD, Gwirtsman HE, Targ EF. Possible adverse drug interactions between fluoxetine and other psychotropics. J Clin Psychopharmacol 1990 Oct; 10(5): 383–4PubMedCrossRef Lock JD, Gwirtsman HE, Targ EF. Possible adverse drug interactions between fluoxetine and other psychotropics. J Clin Psychopharmacol 1990 Oct; 10(5): 383–4PubMedCrossRef
40.
go back to reference Gotoh M, Kato K, Saito M, et al. Effects of disopyramide on detrusor muscle contraction: in vitro experiment and report of 3 cases with disopyramide-induced urinary retention. Urol Int 1987; 42(6): 450–5PubMedCrossRef Gotoh M, Kato K, Saito M, et al. Effects of disopyramide on detrusor muscle contraction: in vitro experiment and report of 3 cases with disopyramide-induced urinary retention. Urol Int 1987; 42(6): 450–5PubMedCrossRef
41.
go back to reference Ziegelbaum M, Lever H. Acute urinary retention associated with flecainide. Cleve Clin J Med 1990 Jan-Feb; 57(1): 86–7PubMed Ziegelbaum M, Lever H. Acute urinary retention associated with flecainide. Cleve Clin J Med 1990 Jan-Feb; 57(1): 86–7PubMed
42.
go back to reference Rao SS, Hofmann LA, Shakil A. Parkinson’s disease: diagnosis and treatment. AmFam Physician 2006 Dec 15; 74(12): 2046–54 Rao SS, Hofmann LA, Shakil A. Parkinson’s disease: diagnosis and treatment. AmFam Physician 2006 Dec 15; 74(12): 2046–54
43.
go back to reference Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson’s disease: report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES) —Part II, late (complicated) Parkinson’s disease. Eur J Neurol 2006 Nov; 13(11): 1186–202PubMedCrossRef Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson’s disease: report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES) —Part II, late (complicated) Parkinson’s disease. Eur J Neurol 2006 Nov; 13(11): 1186–202PubMedCrossRef
44.
go back to reference Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson’s disease: report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section —Part I, early (uncomplicated) Parkinson’s disease. Eur J Neurol 2006 Nov; 13(11): 1170–85PubMedCrossRef Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson’s disease: report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section —Part I, early (uncomplicated) Parkinson’s disease. Eur J Neurol 2006 Nov; 13(11): 1170–85PubMedCrossRef
45.
go back to reference Labetoulle M, Frau E, Le Jeunne C. Systemic adverse effects of topical ocular treatments. Presse Med 2005 Apr 23; 34(8): 589–95CrossRef Labetoulle M, Frau E, Le Jeunne C. Systemic adverse effects of topical ocular treatments. Presse Med 2005 Apr 23; 34(8): 589–95CrossRef
46.
go back to reference Horowitz R, Reynolds S. New oral antihistamines in pediatrics. Pediatr Emerg Care 2004 Feb; 20(2): 143–6PubMedCrossRef Horowitz R, Reynolds S. New oral antihistamines in pediatrics. Pediatr Emerg Care 2004 Feb; 20(2): 143–6PubMedCrossRef
47.
go back to reference Golightly LK, Greos LS. Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs 2005; 65(3): 341–84PubMedCrossRef Golightly LK, Greos LS. Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs 2005; 65(3): 341–84PubMedCrossRef
49.
go back to reference Lin AY, Zahtz G, Myssiorek D. Astemizole-associated urinary retention. Otolaryngol Head Neck Surg 1991 Jun; 104(6): 893–4PubMed Lin AY, Zahtz G, Myssiorek D. Astemizole-associated urinary retention. Otolaryngol Head Neck Surg 1991 Jun; 104(6): 893–4PubMed
50.
go back to reference McGann KP, Pribanich S, Graham JA, et al. Diphenhydramine toxicity in a child with varicella: a case report. J Fam Pract 1992 Aug; 35(2): 210, 3–4PubMed McGann KP, Pribanich S, Graham JA, et al. Diphenhydramine toxicity in a child with varicella: a case report. J Fam Pract 1992 Aug; 35(2): 210, 3–4PubMed
51.
go back to reference Appleton S, Jones T, Poole P, et al. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; (3): CD006101 Appleton S, Jones T, Poole P, et al. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; (3): CD006101
52.
go back to reference Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol 2006 Mar 8; 533(1–3): 36–9PubMedCrossRef Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol 2006 Mar 8; 533(1–3): 36–9PubMedCrossRef
53.
go back to reference Pras E, Stienlauf S, Pinkhas J, et al. Urinary retention associated with ipratropium bromide. DICP 1991 Sep; 25(9): 939–40PubMed Pras E, Stienlauf S, Pinkhas J, et al. Urinary retention associated with ipratropium bromide. DICP 1991 Sep; 25(9): 939–40PubMed
54.
go back to reference Lozewicz S. Bladder outflow obstruction induced by ipratropium bromide. Postgrad Med J 1989 Apr; 65(762): 260–1PubMedCrossRef Lozewicz S. Bladder outflow obstruction induced by ipratropium bromide. Postgrad Med J 1989 Apr; 65(762): 260–1PubMedCrossRef
55.
go back to reference Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006 Oct; 61(10): 854–62PubMedCrossRef Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006 Oct; 61(10): 854–62PubMedCrossRef
56.
go back to reference Tashkin DP. Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease? Curr Opin Pulm Med 2005 Mar; 11(2): 121–8PubMedCrossRef Tashkin DP. Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease? Curr Opin Pulm Med 2005 Mar; 11(2): 121–8PubMedCrossRef
57.
go back to reference Novara G, Galfano A, Ficarra V, et al. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur Urol 2006 Oct; 50(4): 675–83PubMedCrossRef Novara G, Galfano A, Ficarra V, et al. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur Urol 2006 Oct; 50(4): 675–83PubMedCrossRef
58.
go back to reference Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006 Nov 15; 296(19): 2319–28PubMedCrossRef Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006 Nov 15; 296(19): 2319–28PubMedCrossRef
59.
go back to reference Padala PR, Sadiq HJ, Padala KP. Urinary obstruction with citalopram and aripiprazole combination in an elderly patient. J Clin Psychopharmacol 2006 Dec; 26(6): 667–8PubMedCrossRef Padala PR, Sadiq HJ, Padala KP. Urinary obstruction with citalopram and aripiprazole combination in an elderly patient. J Clin Psychopharmacol 2006 Dec; 26(6): 667–8PubMedCrossRef
60.
go back to reference Thor KB. Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence. Urology 2003 Oct; 62 (4 Suppl. 1): 3–9PubMedCrossRef Thor KB. Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence. Urology 2003 Oct; 62 (4 Suppl. 1): 3–9PubMedCrossRef
61.
go back to reference Kasper S. Managing reboxetine-associated urinary hesitancy in a patient with major depressive disorder: a case study. Psychopharmacology (Berl) 2002 Feb; 159(4): 445–6CrossRef Kasper S. Managing reboxetine-associated urinary hesitancy in a patient with major depressive disorder: a case study. Psychopharmacology (Berl) 2002 Feb; 159(4): 445–6CrossRef
62.
go back to reference Kasper S, Wolf R. Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin. Eur Neuropsychopharmacol 2002 Apr; 12(2): 119–22PubMedCrossRef Kasper S, Wolf R. Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin. Eur Neuropsychopharmacol 2002 Apr; 12(2): 119–22PubMedCrossRef
63.
go back to reference Garnier R, Azoyan P, Chataigner D, et al. Acute fluvoxamine poisoning. J Int Med Res 1993 Jul-Aug; 21(4): 197–208PubMed Garnier R, Azoyan P, Chataigner D, et al. Acute fluvoxamine poisoning. J Int Med Res 1993 Jul-Aug; 21(4): 197–208PubMed
64.
go back to reference Hansen LK. Venlafaxine-induced increase in urinary frequency in 3 women. J Clin Psychiatry 2004 Jun; 65(6): 877–8.PubMedCrossRef Hansen LK. Venlafaxine-induced increase in urinary frequency in 3 women. J Clin Psychiatry 2004 Jun; 65(6): 877–8.PubMedCrossRef
65.
go back to reference Moghaddas F, Lidfeldt J, Nerbrand C, et al. Prevalence of urinary incontinence in relation to self-reported depression, intake of serotonergic antidepressants, and hormone therapy in middle-aged women: a report from the Women’s Health in the Lund Area study. Menopause 2005 May-Jun; 12(3): 318–24PubMedCrossRef Moghaddas F, Lidfeldt J, Nerbrand C, et al. Prevalence of urinary incontinence in relation to self-reported depression, intake of serotonergic antidepressants, and hormone therapy in middle-aged women: a report from the Women’s Health in the Lund Area study. Menopause 2005 May-Jun; 12(3): 318–24PubMedCrossRef
66.
go back to reference Shearer WT, Schreiner RL, Marshall RE. Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J Pediatr 1972 Sep; 81(3): 570–2PubMedCrossRef Shearer WT, Schreiner RL, Marshall RE. Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J Pediatr 1972 Sep; 81(3): 570–2PubMedCrossRef
67.
go back to reference Remick RA. Anticholinergic side effects of tricyclic antidepressants and their management. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12(2–3): 225–31PubMedCrossRef Remick RA. Anticholinergic side effects of tricyclic antidepressants and their management. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12(2–3): 225–31PubMedCrossRef
68.
go back to reference De Lima MS, Hotopf M. Benefits and risks of pharmacotherapy for dysthymia: a systematic appraisal of the evidence. Drug Saf 2003; 26(1): 55–64PubMedCrossRef De Lima MS, Hotopf M. Benefits and risks of pharmacotherapy for dysthymia: a systematic appraisal of the evidence. Drug Saf 2003; 26(1): 55–64PubMedCrossRef
69.
go back to reference Parker J, Lahmeyer H. Maprotiline poisoning: a case of cardiotoxicity and myoclonic seizures. J Clin Psychiatry 1984 Jul; 45(7): 312–4PubMed Parker J, Lahmeyer H. Maprotiline poisoning: a case of cardiotoxicity and myoclonic seizures. J Clin Psychiatry 1984 Jul; 45(7): 312–4PubMed
70.
go back to reference Caksen H, Odabas D. Urinary retention due to clonazepam in a child with dyskinetic cerebral palsy. J Emerg Med 2004 Feb; 26(2): 244PubMedCrossRef Caksen H, Odabas D. Urinary retention due to clonazepam in a child with dyskinetic cerebral palsy. J Emerg Med 2004 Feb; 26(2): 244PubMedCrossRef
71.
go back to reference Maany I, Greenfield H, Dhopesh V, et al. Urinary retention as a possible complication of long-term diazepam abuse [letter]. Am J Psychiatry 1991 May; 148(5): 685PubMed Maany I, Greenfield H, Dhopesh V, et al. Urinary retention as a possible complication of long-term diazepam abuse [letter]. Am J Psychiatry 1991 May; 148(5): 685PubMed
72.
go back to reference Burger DH, Kappetein AP, Boutkan H, et al. Prevention of urinary retention after general surgery: a controlled trial of carbachol/diazepam versus alfusozine. J Am Coll Surg 1997 Sep; 185(3): 234–6PubMed Burger DH, Kappetein AP, Boutkan H, et al. Prevention of urinary retention after general surgery: a controlled trial of carbachol/diazepam versus alfusozine. J Am Coll Surg 1997 Sep; 185(3): 234–6PubMed
73.
go back to reference O’Reilly PH. Postoperative urinary retention in men. BMJ (Clin Res Ed) 1991 Apr 13; 302(6781): 864CrossRef O’Reilly PH. Postoperative urinary retention in men. BMJ (Clin Res Ed) 1991 Apr 13; 302(6781): 864CrossRef
74.
go back to reference Meyboom RH, Brodie-Meijer CC, Diemont WL, et al. Bladder dysfunction during the use of tramadol. Pharmacoepidemiol Drug Saf 1999 Apr; 8 Suppl. 1: S63–4PubMedCrossRef Meyboom RH, Brodie-Meijer CC, Diemont WL, et al. Bladder dysfunction during the use of tramadol. Pharmacoepidemiol Drug Saf 1999 Apr; 8 Suppl. 1: S63–4PubMedCrossRef
75.
go back to reference Malinovsky JM, Le Normand L, Lepage JY, et al. The urodynamic effects of intravenous opioids and ketoprofen in humans. Anesth Analg 1998 Aug; 87(2): 456–61PubMed Malinovsky JM, Le Normand L, Lepage JY, et al. The urodynamic effects of intravenous opioids and ketoprofen in humans. Anesth Analg 1998 Aug; 87(2): 456–61PubMed
76.
go back to reference Koch CA, Grinberg GG, Farley DR. Incidence and risk factors for urinary retention after endoscopic hernia repair. Am J Surg 2006 Mar; 191(3): 381–5PubMedCrossRef Koch CA, Grinberg GG, Farley DR. Incidence and risk factors for urinary retention after endoscopic hernia repair. Am J Surg 2006 Mar; 191(3): 381–5PubMedCrossRef
77.
go back to reference Dolin SJ, Cashman JN. Tolerability of acute postoperative pain management: nausea, vomiting, sedation, pruritus, and urinary retention: evidence from published data. Br J Anaesth 2005 Nov; 95(5): 584–91PubMedCrossRef Dolin SJ, Cashman JN. Tolerability of acute postoperative pain management: nausea, vomiting, sedation, pruritus, and urinary retention: evidence from published data. Br J Anaesth 2005 Nov; 95(5): 584–91PubMedCrossRef
78.
go back to reference Murray K. Acute urinary retention associated with sublingual buprenorphine. BMJ (Clin Res Ed) 1983 Mar 5; 286(6367): 763–4CrossRef Murray K. Acute urinary retention associated with sublingual buprenorphine. BMJ (Clin Res Ed) 1983 Mar 5; 286(6367): 763–4CrossRef
79.
go back to reference Chen Y-P, Chen S-R, Pan H-L. Systemic morphine inhibits dorsal horn projection neurons through spinal cholinergic system independent of descending pathways. J Pharmacol Exp Ther 2005; 314(2): 611–7PubMedCrossRef Chen Y-P, Chen S-R, Pan H-L. Systemic morphine inhibits dorsal horn projection neurons through spinal cholinergic system independent of descending pathways. J Pharmacol Exp Ther 2005; 314(2): 611–7PubMedCrossRef
80.
go back to reference Sakakibara R, Uchiyama T, Asahina M, et al. Amezinium metilsulfate, a sympathomimetic agent, may increase the risk of urinary retention in multiple system atrophy. Clin Auton Res 2003 Feb; 13(1): 51–3PubMedCrossRef Sakakibara R, Uchiyama T, Asahina M, et al. Amezinium metilsulfate, a sympathomimetic agent, may increase the risk of urinary retention in multiple system atrophy. Clin Auton Res 2003 Feb; 13(1): 51–3PubMedCrossRef
81.
82.
go back to reference Glidden RS, DiBona FJ. Urinary retention associated with ephedrine. J Pediatr 1977 Jun; 90(6): 1013–4PubMedCrossRef Glidden RS, DiBona FJ. Urinary retention associated with ephedrine. J Pediatr 1977 Jun; 90(6): 1013–4PubMedCrossRef
83.
go back to reference Taylor III JA, Kuchel GA. Detrusor underactivity: clinical features and pathogenesis of an underdiagnosed geriatric condition. J Am Geriatr Soc 2006 Dec; 54(12): 1920–32PubMedCrossRef Taylor III JA, Kuchel GA. Detrusor underactivity: clinical features and pathogenesis of an underdiagnosed geriatric condition. J Am Geriatr Soc 2006 Dec; 54(12): 1920–32PubMedCrossRef
84.
go back to reference Inman DS, Greene D. The agony and the ecstasy: acute urinary retention after MDMA abuse. BJU Int 2003 Jan; 91(1): 123PubMedCrossRef Inman DS, Greene D. The agony and the ecstasy: acute urinary retention after MDMA abuse. BJU Int 2003 Jan; 91(1): 123PubMedCrossRef
85.
go back to reference Bryden AA, Rothwell PJ, O’Reilly PH. Urinary retention with misuse of “ecstasy”. BMJ 1995 Feb 25; 310(6978): 504PubMedCrossRef Bryden AA, Rothwell PJ, O’Reilly PH. Urinary retention with misuse of “ecstasy”. BMJ 1995 Feb 25; 310(6978): 504PubMedCrossRef
86.
go back to reference Park JM, Houck CS, Sethna NF, et al. Ketorolac suppresses postoperative bladder spasms after pediatric ureteral reimplantation. Anesth Analg 2000 Jul; 91(1): 11–5PubMed Park JM, Houck CS, Sethna NF, et al. Ketorolac suppresses postoperative bladder spasms after pediatric ureteral reimplantation. Anesth Analg 2000 Jul; 91(1): 11–5PubMed
87.
go back to reference Gruenenfelder J, McGuire EJ, Faerber GJ. Acute urinary retention associated with the use of cyclooxygenase-2 inhibitors [letter]. J Urol 2002 Sep; 168(3): 1106PubMedCrossRef Gruenenfelder J, McGuire EJ, Faerber GJ. Acute urinary retention associated with the use of cyclooxygenase-2 inhibitors [letter]. J Urol 2002 Sep; 168(3): 1106PubMedCrossRef
88.
go back to reference Verhamme KM, Dieleman JP, Van Wijk MA, et al. Nonsteroidal anti-inflammatory drugs and increased risk of acute urinary retention. Arch Intern Med 2005 Jul 11; 165(13): 1547–51PubMedCrossRef Verhamme KM, Dieleman JP, Van Wijk MA, et al. Nonsteroidal anti-inflammatory drugs and increased risk of acute urinary retention. Arch Intern Med 2005 Jul 11; 165(13): 1547–51PubMedCrossRef
89.
go back to reference Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs 2004; 64(15): 1643–56PubMedCrossRef Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs 2004; 64(15): 1643–56PubMedCrossRef
90.
go back to reference Owens RG, Karram MM. Comparative tolerability of drug therapies used to treat incontinence and enuresis. Drug Saf 1998 Aug; 19(2): 123–39PubMedCrossRef Owens RG, Karram MM. Comparative tolerability of drug therapies used to treat incontinence and enuresis. Drug Saf 1998 Aug; 19(2): 123–39PubMedCrossRef
91.
go back to reference Haeusler G, Leitich H, van Trotsenburg M, et al. Drug therapy of urinary urge incontinence: a systematic review. Obstet Gynecol 2002 Nov; 100 (5 Pt 1): 1003–16PubMedCrossRef Haeusler G, Leitich H, van Trotsenburg M, et al. Drug therapy of urinary urge incontinence: a systematic review. Obstet Gynecol 2002 Nov; 100 (5 Pt 1): 1003–16PubMedCrossRef
92.
go back to reference Khurana V, Nehme O, Khurana R, et al. Urinary retention secondary to detrusor muscle hypofunction after botulinum toxin injection for achalasia. Am J Gastroenterol 2001 Nov; 96(11): 3211–2PubMedCrossRef Khurana V, Nehme O, Khurana R, et al. Urinary retention secondary to detrusor muscle hypofunction after botulinum toxin injection for achalasia. Am J Gastroenterol 2001 Nov; 96(11): 3211–2PubMedCrossRef
93.
go back to reference Eicher JC, Chalopin JM, Tanter Y, et al. Nicardipine and urinary retention [letter]. JAMA 1987 Dec 18; 258(23): 3388PubMedCrossRef Eicher JC, Chalopin JM, Tanter Y, et al. Nicardipine and urinary retention [letter]. JAMA 1987 Dec 18; 258(23): 3388PubMedCrossRef
94.
go back to reference Winge K, Werdelin LM, Nielsen KK, et al. Effects of dopaminergic treatment on bladder function in Parkinson’s disease. Neurourol Urodyn 2004; 23(7): 689–96PubMedCrossRef Winge K, Werdelin LM, Nielsen KK, et al. Effects of dopaminergic treatment on bladder function in Parkinson’s disease. Neurourol Urodyn 2004; 23(7): 689–96PubMedCrossRef
95.
go back to reference Jotkowitz S. Urinary retention as complication of levodopa therapy [letter]. JAMA 1976 Jun 14; 235(24): 2586PubMedCrossRef Jotkowitz S. Urinary retention as complication of levodopa therapy [letter]. JAMA 1976 Jun 14; 235(24): 2586PubMedCrossRef
96.
go back to reference Tfayli A, Hentschel P, Madajewicz S, et al. Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors. J Neurooncol 1999 Mar; 42(1): 73–7PubMedCrossRef Tfayli A, Hentschel P, Madajewicz S, et al. Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors. J Neurooncol 1999 Mar; 42(1): 73–7PubMedCrossRef
97.
go back to reference Taieb S, Trillet-Lenoir V, Rambaud L, et al. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 2002 May 1; 94(9): 2434–40PubMedCrossRef Taieb S, Trillet-Lenoir V, Rambaud L, et al. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 2002 May 1; 94(9): 2434–40PubMedCrossRef
98.
go back to reference Bay A, Oner AF, Etlik O, et al. Myelopathy due to intrathecal chemotherapy: report of six cases. J Pediatr Hematol Oncol 2005 May; 27(5): 270–2PubMedCrossRef Bay A, Oner AF, Etlik O, et al. Myelopathy due to intrathecal chemotherapy: report of six cases. J Pediatr Hematol Oncol 2005 May; 27(5): 270–2PubMedCrossRef
99.
go back to reference McQuillan O, Higgins SP. Acute urinary retention following self treatment of genital warts with imiquimod 5% cream. Sex Transm Infect 2004 Oct; 80(5): 419–20PubMedCrossRef McQuillan O, Higgins SP. Acute urinary retention following self treatment of genital warts with imiquimod 5% cream. Sex Transm Infect 2004 Oct; 80(5): 419–20PubMedCrossRef
100.
go back to reference Friedman AJ. Acute urinary retention after gonadotropin-releasing hormone agonist treatment for leiomyomata uteri. Fertil Steril 1993 Mar; 59(3): 677–8PubMed Friedman AJ. Acute urinary retention after gonadotropin-releasing hormone agonist treatment for leiomyomata uteri. Fertil Steril 1993 Mar; 59(3): 677–8PubMed
101.
go back to reference Charalabopoulos K, Papalimneou V, Charalabopoulos A, et al. Two new adverse effects of isotretinoin [letter]. Br J Dermatol 2003 Mar; 148(3): 593PubMedCrossRef Charalabopoulos K, Papalimneou V, Charalabopoulos A, et al. Two new adverse effects of isotretinoin [letter]. Br J Dermatol 2003 Mar; 148(3): 593PubMedCrossRef
102.
go back to reference Meythaler JM, Guin-Renfroe S, Brunner RC, et al. Intrathecal baclofen for spastic hypertonia from stroke. Stroke 2001 Sep; 32(9): 2099–109PubMedCrossRef Meythaler JM, Guin-Renfroe S, Brunner RC, et al. Intrathecal baclofen for spastic hypertonia from stroke. Stroke 2001 Sep; 32(9): 2099–109PubMedCrossRef
103.
go back to reference de Moor RA, Diemont WL, Visser MO, et al. Urinary retention in 2 children after the use of antiemetic agents during acute gastroenteritis [in Dutch]. Ned Tijdschr Geneeskd 2005 Jun 25; 149(26): 1472–4PubMed de Moor RA, Diemont WL, Visser MO, et al. Urinary retention in 2 children after the use of antiemetic agents during acute gastroenteritis [in Dutch]. Ned Tijdschr Geneeskd 2005 Jun 25; 149(26): 1472–4PubMed
104.
go back to reference Kohli-Kumar M, Pearson AD, Sharkey I, et al. Urinary retention: an unusual dystonic reaction to continuous metoclopramide infusion. DICP 1991 May; 25(5): 469–70PubMed Kohli-Kumar M, Pearson AD, Sharkey I, et al. Urinary retention: an unusual dystonic reaction to continuous metoclopramide infusion. DICP 1991 May; 25(5): 469–70PubMed
105.
go back to reference Steiner I, Birmanns B. Carbamazepine-induced urinary retention in long-standing diabetes mellitus. Neurology 1993 Sep; 43(9): 1855–6PubMedCrossRef Steiner I, Birmanns B. Carbamazepine-induced urinary retention in long-standing diabetes mellitus. Neurology 1993 Sep; 43(9): 1855–6PubMedCrossRef
106.
go back to reference Saborio DV, Kennedy II WA, Hoke GP. Acute urinary retention secondary to urethral inflammation from a vaginal contraceptive suppository in a 17-year-old boy. Urol Int 1997; 58(2): 128–30PubMedCrossRef Saborio DV, Kennedy II WA, Hoke GP. Acute urinary retention secondary to urethral inflammation from a vaginal contraceptive suppository in a 17-year-old boy. Urol Int 1997; 58(2): 128–30PubMedCrossRef
107.
go back to reference Chua KS, Kong KH. An unusual case of Dantrolene sodium-induced urinary retention in post-traumatic minimally responsive state. Brain Inj 2005 Nov; 19(12): 1063–6PubMedCrossRef Chua KS, Kong KH. An unusual case of Dantrolene sodium-induced urinary retention in post-traumatic minimally responsive state. Brain Inj 2005 Nov; 19(12): 1063–6PubMedCrossRef
108.
go back to reference Owens GR, Tannenbaum R. Theophylline-induced urinary retention. Ann Intern Med 1981 Feb; 94(2): 212–3PubMed Owens GR, Tannenbaum R. Theophylline-induced urinary retention. Ann Intern Med 1981 Feb; 94(2): 212–3PubMed
109.
110.
go back to reference Tyson LB, Gralla RJ, Clark RA, et al. Phase 1 trial of levonantradol in chemotherapy-induced emesis. Am J Clin Oncol 1985 Dec; 8(6): 528–32PubMedCrossRef Tyson LB, Gralla RJ, Clark RA, et al. Phase 1 trial of levonantradol in chemotherapy-induced emesis. Am J Clin Oncol 1985 Dec; 8(6): 528–32PubMedCrossRef
111.
go back to reference McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 Dec 18; 349(25): 2387–98PubMedCrossRef McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 Dec 18; 349(25): 2387–98PubMedCrossRef
112.
go back to reference Hameed A, Charles TJ. Cholinergic crisis following treatment of postoperative urinary retention with distigmine bromide. Br J Clin Pract 1994 Mar–Apr; 48(2): 103–4PubMed Hameed A, Charles TJ. Cholinergic crisis following treatment of postoperative urinary retention with distigmine bromide. Br J Clin Pract 1994 Mar–Apr; 48(2): 103–4PubMed
113.
go back to reference Barendrecht MM, Oelke M, Laguna MP, et al. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int 2007 Apr; 99(4): 749–52PubMedCrossRef Barendrecht MM, Oelke M, Laguna MP, et al. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int 2007 Apr; 99(4): 749–52PubMedCrossRef
114.
go back to reference Rawal N, Mollefors K, Axelsson K, et al. Naloxone reversal of urinary retention after epidural morphine [letter]. Lancet 1981 Dec 19–26; 2(8260-61): 1411PubMedCrossRef Rawal N, Mollefors K, Axelsson K, et al. Naloxone reversal of urinary retention after epidural morphine [letter]. Lancet 1981 Dec 19–26; 2(8260-61): 1411PubMedCrossRef
115.
go back to reference Wang J, Pennefather S, Russell G. Low-dose naloxone in the treatment of urinary retention during extradural fentanyl causes excessive reversal of analgesia. Br J Anaesth 1998 Apr; 80(4): 565–6PubMedCrossRef Wang J, Pennefather S, Russell G. Low-dose naloxone in the treatment of urinary retention during extradural fentanyl causes excessive reversal of analgesia. Br J Anaesth 1998 Apr; 80(4): 565–6PubMedCrossRef
116.
go back to reference Malinovsky JM, Lepage JY, Karam G, et al. Nalbuphine reverses urinary effects of epidural morphine: a case report. J Clin Anesthes 2002 Nov; 14(7): 535–8CrossRef Malinovsky JM, Lepage JY, Karam G, et al. Nalbuphine reverses urinary effects of epidural morphine: a case report. J Clin Anesthes 2002 Nov; 14(7): 535–8CrossRef
117.
go back to reference Walder B, Schafer M, Henzi I, et al. Efficacy and safety of patient-controlled opioid analgesia for acute postoperative pain: a quantitative systematic review. Acta Anaesthesiol Scand 2001 Aug; 45(7): 795–804PubMedCrossRef Walder B, Schafer M, Henzi I, et al. Efficacy and safety of patient-controlled opioid analgesia for acute postoperative pain: a quantitative systematic review. Acta Anaesthesiol Scand 2001 Aug; 45(7): 795–804PubMedCrossRef
118.
go back to reference Kehlet H, Dahl JB. The value of “multimodal” or “balanced analgesia” in postoperative pain treatment. Anesth Analg 1993 Nov; 77(5): 1048–56PubMedCrossRef Kehlet H, Dahl JB. The value of “multimodal” or “balanced analgesia” in postoperative pain treatment. Anesth Analg 1993 Nov; 77(5): 1048–56PubMedCrossRef
119.
go back to reference Remy C, Marret E, Bonnet F. Effects of acetaminophen on morphine side-effects and consumption after major surgery: meta-analysis of randomized controlled trials. Br J Anaesth 2005 Apr; 94(4): 505–13PubMedCrossRef Remy C, Marret E, Bonnet F. Effects of acetaminophen on morphine side-effects and consumption after major surgery: meta-analysis of randomized controlled trials. Br J Anaesth 2005 Apr; 94(4): 505–13PubMedCrossRef
120.
go back to reference Turan A, Karamanlioglu B, Memis D, et al. Analgesic effects of gabapentin after spinal surgery. Anesthesiology 2004 Apr; 100(4): 935–8PubMedCrossRef Turan A, Karamanlioglu B, Memis D, et al. Analgesic effects of gabapentin after spinal surgery. Anesthesiology 2004 Apr; 100(4): 935–8PubMedCrossRef
121.
go back to reference Marret E, Kurdi O, Zufferey P, et al. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: meta-analysis of randomized controlled trials. Anesthesiology 2005 Jun; 102(6): 1249–60PubMedCrossRef Marret E, Kurdi O, Zufferey P, et al. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: meta-analysis of randomized controlled trials. Anesthesiology 2005 Jun; 102(6): 1249–60PubMedCrossRef
122.
go back to reference Romsing J, Moiniche S, Mathiesen O, et al. Reduction of opioid-related adverse events using opioid-sparing analgesia with COX-2 inhibitors lacks documentation: a systematic review. Acta Anaesthesiol Scand 2005 Feb; 49(2): 133–42PubMedCrossRef Romsing J, Moiniche S, Mathiesen O, et al. Reduction of opioid-related adverse events using opioid-sparing analgesia with COX-2 inhibitors lacks documentation: a systematic review. Acta Anaesthesiol Scand 2005 Feb; 49(2): 133–42PubMedCrossRef
123.
go back to reference Gottesman L, Milsom JW, Mazier WP. The use of anxiolytic and parasympathomimetic agents in the treatment of postoperative urinary retention following anorectal surgery: a prospective, randomized, double-blind study. Dis Colon Rectum 1989 Oct; 32(10): 867–70PubMedCrossRef Gottesman L, Milsom JW, Mazier WP. The use of anxiolytic and parasympathomimetic agents in the treatment of postoperative urinary retention following anorectal surgery: a prospective, randomized, double-blind study. Dis Colon Rectum 1989 Oct; 32(10): 867–70PubMedCrossRef
124.
go back to reference Hershberger JM, Milad MP. A randomized clinical trial of lorazepam for the reduction of postoperative urinary retention. Obstet Gynecol 2003 Aug; 102(2): 311–6PubMedCrossRef Hershberger JM, Milad MP. A randomized clinical trial of lorazepam for the reduction of postoperative urinary retention. Obstet Gynecol 2003 Aug; 102(2): 311–6PubMedCrossRef
125.
go back to reference Szabadi E. Doxazosin for reboxetine-induced urinary hesitancy. Br J Psychiatry 1998 Nov; 173: 441–2PubMedCrossRef Szabadi E. Doxazosin for reboxetine-induced urinary hesitancy. Br J Psychiatry 1998 Nov; 173: 441–2PubMedCrossRef
Metadata
Title
Drug-Induced Urinary Retention
Incidence, Management and Prevention
Authors
Dr Katia M. C. Verhamme
Miriam C. J. M. Sturkenboom
Bruno H. Ch Stricker
Ruud Bosch
Publication date
01-05-2008
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 5/2008
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200831050-00002

Other articles of this Issue 5/2008

Drug Safety 5/2008 Go to the issue